Your browser doesn't support javascript.
COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop.
Clerbaux, Laure-Alix; Amigó, Núria; Amorim, Maria João; Bal-Price, Anna; Batista Leite, Sofia; Beronius, Anna; Bezemer, Gillina F G; Bostroem, Ann-Charlotte; Carusi, Annamaria; Coecke, Sandra; Concha, Rachel; Daskalopoulos, Evangelos P; De Bernardi, Francesca; Edrosa, Eizleayne; Edwards, Steve W; Filipovska, Julija; Garcia-Reyero, Natàlia; Gavins, Felicity N E; Halappanavar, Sabina; Hargreaves, Alan J; Hogberg, Helena T; Huynh, Mylène T; Jacobson, Daniel; Josephs-Spaulding, Jonathan; Kim, Young Jun; Kong, Hyun Joon; Krebs, Catharine E; Lam, Ann; Landesmann, Brigitte; Layton, Adrienne; Lee, Yong Oh; Macmillan, Donna S; Mantovani, Alberto; Margiotta-Casaluci, Luigi; Martens, Marvin; Masereeuw, Rosalinde; Mayasich, Sally A; Mei, Liang Merlin; Mortensen, Holly; Munoz Pineiro, Amalia; Nymark, Penny; Ohayon, Elan; Ojasi, Joshi; Paini, Alicia; Parissis, Nikolaos; Parvatam, Surat; Pistollato, Francesca; Sachana, Magdalini; Sørli, Jorid Birkelund; Sullivan, Kristie M.
  • Clerbaux LA; European Commission, Joint Research Centre, Ispra, Italy.
  • Amigó N; Biosfer Teslab, Reus, Spain.
  • Amorim MJ; Instituto Gulbenkian de Ciência, Lisbon, Portugal.
  • Bal-Price A; European Commission, Joint Research Centre, Ispra, Italy.
  • Batista Leite S; European Commission, Joint Research Centre, Ispra, Italy.
  • Beronius A; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Bezemer GFG; Impact Station, Hilversum, The Netherlands.
  • Bostroem AC; European Commission, Joint Research Centre, Ispra, Italy.
  • Carusi A; Interchange Research, London, UK.
  • Coecke S; European Commission, Joint Research Centre, Ispra, Italy.
  • Concha R; Fairleigh Dickinson University, Green Neuroscience Laboratory, San Diego, CA, USA
  • Daskalopoulos EP; European Commission, Joint Research Centre, Ispra, Italy.
  • De Bernardi F; Division of Otorhinolaryngology, Department of Biotechnologies and Life Sciences, University of Insubria, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
  • Edrosa E; Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA
  • Edwards SW; RTI International, Research Triangle Park, NC, USA.
  • Filipovska J; Independent scientist, Ohrid, North Macedonia.
  • Garcia-Reyero N; US Army Engineer Research and Development Center, Vicksburg, MS, USA.
  • Gavins FNE; The Centre for Inflammation Research and Translational Medicine (CIRTM), Brunel University London, London, UK.
  • Halappanavar S; Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada.
  • Hargreaves AJ; School of Science and Technology, Nottingham Trent University, Nottingham, UK.
  • Hogberg HT; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Huynh MT; Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
  • Jacobson D; Biosciences, Oak Ridge National Laboratory, Oak Ridge, TN, USA.
  • Josephs-Spaulding J; Institute for Experimental Medicine, Kiel University, Kiel, Germany.
  • Kim YJ; Korea Institute of Science and Technology Europe Forschungsgesellschaft mbH, Saarbrücken, Germany.
  • Kong HJ; University of Illinois at Urbana-Champaign, Champaign, IL, USA.
  • Krebs CE; Physicians Committee for Responsible Medicine, Washington, DC, USA.
  • Lam A; Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA
  • Landesmann B; European Commission, Joint Research Centre, Ispra, Italy.
  • Layton A; US Consumer Product Safety Commission, Bethesda, MD, USA.
  • Lee YO; Korea Institute of Science and Technology Europe Forschungsgesellschaft mbH, Saarbrücken, Germany.
  • Macmillan DS; Humane Society International, Washington, DC, USA.
  • Mantovani A; Istituto Superiore di Sanità, Rome, Italy.
  • Margiotta-Casaluci L; The Centre for Inflammation Research and Translational Medicine (CIRTM), Brunel University London, London, UK.
  • Martens M; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands.
  • Masereeuw R; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Mayasich SA; University of Wisconsin-Madison Aquatic Sciences Center at US EPA, Duluth, MN, USA.
  • Mei LM; US EPA, Durham, NC, USA.
  • Mortensen H; US EPA, Durham, NC, USA.
  • Munoz Pineiro A; European Commission, Joint Research Centre, Geel, Belgium.
  • Nymark P; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Ohayon E; Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA
  • Ojasi J; Hiranandani College of Pharmacy, Mumbai, India.
  • Paini A; European Commission, Joint Research Centre, Ispra, Italy.
  • Parissis N; European Commission, Joint Research Centre, Ispra, Italy.
  • Parvatam S; Centre for Predictive Human Model Systems Atal Incubation Centre - Centre for Cellular and Molecular Biology Habsiguda, Hyderabad, India.
  • Pistollato F; European Commission, Joint Research Centre, Ispra, Italy. Francesca.PISTOLLATO@ec.europa.eu.
  • Sachana M; Environment Health and Safety Division, Environment Directorate, Organisation for Economic Cooperation and Development (OECD), Paris, France.
  • Sørli JB; The National Research Centre for the Working Environment, Copenhagen, Denmark.
  • Sullivan KM; Physicians Committee for Responsible Medicine, Washington, DC, USA.
ALTEX ; 39(2): 322­335, 2022.
Article in English | MEDLINE | ID: covidwho-1626699
ABSTRACT
On April 28-29, 2021, 50 scientists from different fields of expertise met for the 3rd online CIAO workshop. The CIAO project "Modelling the Pathogenesis of COVID-19 using the Adverse Outcome Pathway (AOP) framework" aims at building a holistic assembly of the available scientific knowledge on COVID-19 using the AOP framework. An individual AOP depicts the disease progression from the initial contact with the SARS-CoV-2 virus through biological key events (KE) toward an adverse outcome such as respiratory distress, anosmia or multiorgan failure. Assembling the individual AOPs into a network highlights shared KEs as central biological nodes involved in multiple outcomes observed in COVID-19 patients. During the workshop, the KEs and AOPs established so far by the CIAO members were presented and posi­tioned on a timeline of the disease course. Modulating factors influencing the progression and severity of the disease were also addressed as well as factors beyond purely biological phenomena. CIAO relies on an interdisciplinary crowd­sourcing effort, therefore, approaches to expand the CIAO network by widening the crowd and reaching stakeholders were also discussed. To conclude the workshop, it was decided that the AOPs/KEs will be further consolidated, inte­grating virus variants and long COVID when relevant, while an outreach campaign will be launched to broaden the CIAO scientific crowd.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Adverse Outcome Pathways / COVID-19 Type of study: Prognostic study Topics: Long Covid / Variants Limits: Humans Language: English Journal: ALTEX Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Altex.2112161

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Adverse Outcome Pathways / COVID-19 Type of study: Prognostic study Topics: Long Covid / Variants Limits: Humans Language: English Journal: ALTEX Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Altex.2112161